Tramiprosate

被引:35
作者
Wright, Tamsin M. [1 ]
机构
[1] Prous Sci, Dept Med Informat, E-08025 Barcelona, Spain
关键词
D O I
10.1358/dot.2006.42.5.973584
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Current treatment options for patients with Alzheimer's disease are limited to providing symptomatic relief, with no effects on the underlying pathophysiology. However, a greater understanding of the importance of beta-amyloid peptides (Abeta) in the pathogenesis of this disease has led to the investigation of a number of potential antiamyloid therapies, of which tramiprosate (Neurochem Inc.) is in the most advanced stage of development. Tramiprosate is a glycosaminoglycan (GAG) mimetic designed to interfere with the actions of Abeta early in the cascade of amyloidogenic events. Preclinical data have shown that tramiprosate reduces brain and plasma levels of Abeta, prevents fibril formation and exerts cytoprotective effects in the brain. The pharmacological effects have also been demonstrated in clinical trials of patients with mild to moderate Alzheimer's disease. Promising findings for the efficacy of tramiprosate, indicated by improvement or stabilization of cognitive function, have been shown in phase 11 clinical trials and open-label extensions of these studies. Furthermore, tramiprosate appears to be well tolerated with no reports of safety concerns. This article reviews the unique mode of action of tramiprosate and summarizes the available clinical information on the effects of tramiprosate in patients with Alzheimer's disease. (c) 2006 Prous Science. All rights reserved.
引用
收藏
页码:291 / 298
页数:8
相关论文
共 55 条
[21]  
GERVAIS F, 2002, INT S MED CHEM NEUR, V188
[22]   SEGREGATION OF A MISSENSE MUTATION IN THE AMYLOID PRECURSOR PROTEIN GENE WITH FAMILIAL ALZHEIMERS-DISEASE [J].
GOATE, A ;
CHARTIERHARLIN, MC ;
MULLAN, M ;
BROWN, J ;
CRAWFORD, F ;
FIDANI, L ;
GIUFFRA, L ;
HAYNES, A ;
IRVING, N ;
JAMES, L ;
MANT, R ;
NEWTON, P ;
ROOKE, K ;
ROQUES, P ;
TALBOT, C ;
PERICAKVANCE, M ;
ROSES, A ;
WILLIAMSON, R ;
ROSSOR, M ;
OWEN, M ;
HARDY, J .
NATURE, 1991, 349 (6311) :704-706
[23]   Alzheimer's disease-affected brain:: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss [J].
Gong, YS ;
Chang, L ;
Viola, KL ;
Lacor, PN ;
Lambert, MP ;
Finch, CE ;
Krafft, GA ;
Klein, WL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) :10417-10422
[24]   PROTEOGLYCAN-MEDIATED INHIBITION OF A-BETA PROTEOLYSIS - A POTENTIAL CAUSE OF SENILE PLAQUE ACCUMULATION [J].
GUPTABANSAL, R ;
FREDERICKSON, RCA ;
BRUNDEN, KR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (31) :18666-18671
[25]   Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease -: A comparative cerebrospinal fluid study [J].
Hampel, H ;
Buerger, K ;
Zinkowski, R ;
Teipel, SJ ;
Goernitz, A ;
Andreasen, N ;
Sjoegren, M ;
DeBernardis, J ;
Kerkman, D ;
Ishiguro, K ;
Ohno, H ;
Vanmechelen, E ;
Vanderstichele, H ;
McCulloch, C ;
Möller, HJ ;
Davies, P ;
Blennow, K .
ARCHIVES OF GENERAL PSYCHIATRY, 2004, 61 (01) :95-102
[26]  
HAROUTUNIAN V, 2006, IN PRESS NEUROBIOL A
[27]   Cerebrospinal fluid levels of amyloid precursor protein and amyloid β-peptide in Alzheimer's disease and major depression -: inverse correlation with dementia severity [J].
Hock, C ;
Golombowski, S ;
Müller-Spahn, F ;
Naser, W ;
Beyreuther, K ;
Mönning, U ;
Schenk, D ;
Vigo-Pelfrey, C ;
Bush, AM ;
Moir, R ;
Tanzi, RE ;
Growdon, JH ;
Nitsch, RM .
EUROPEAN NEUROLOGY, 1998, 39 (02) :111-118
[28]   Cerebrospinal fluid tau, Aβ1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia [J].
Jia, JP ;
Meng, R ;
Sun, YX ;
Sun, WJ ;
Ji, XM ;
Jia, LF .
NEUROSCIENCE LETTERS, 2005, 383 (1-2) :12-16
[29]   Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases [J].
Kayed, R ;
Sokolov, Y ;
Edmonds, B ;
McIntire, TM ;
Milton, SC ;
Hall, JE ;
Glabe, CG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (45) :46363-46366
[30]   Sequence determinants of enhanced amyloidogenicity of Alzheimer Aβ42 peptide relative to Aβ40 [J].
Kim, W ;
Hecht, MH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (41) :35069-35076